<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recently, the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> has focused on <z:chebi fb="11" ids="22586">antioxidant</z:chebi> therapies, where <z:mp ids='MP_0003674'>oxidative stress</z:mp> is implicated </plain></SENT>
<SENT sid="1" pm="."><plain>The preventive and therapeutic potential of plant compounds on <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> has been intensively studied because many of them contain <z:chebi fb="11" ids="22586">antioxidant</z:chebi> properties </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="28088">Genistein</z:chebi>, one of the active ingredients in soybean, possesses many bioactivities </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we investigated the potential neuroprotective effects of <z:chebi fb="0" ids="28088">genistein</z:chebi> and its possible mechanism of action in a <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> mouse model </plain></SENT>
<SENT sid="4" pm="."><plain>Mice were pretreated with <z:chebi fb="0" ids="28088">genistein</z:chebi> (2.5, 5, and 10mg/kg) or vehicle orally once daily for 14 consecutive days before transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> was performed </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="28088">Genistein</z:chebi> at doses of 2.5-10mg/kg significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, improved the neurological deficit and prevented cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, <z:chebi fb="0" ids="28088">genistein</z:chebi> pretreatment was shown to inhibit the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced reactive oxygen species (ROS) production, enhance the activities of <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzymes <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD) and <z:chebi fb="0" ids="16856">glutathione</z:chebi> peroxidase (GPx), and decrease levels of malondialdehyde (<z:chebi fb="14" ids="32506">MDA</z:chebi>) in <z:hpo ids='HP_0001297'>stroke</z:hpo> mice </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, <z:chebi fb="0" ids="28088">genistein</z:chebi> reversed the mitochondria dysfunction after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, as evidenced by decreasing mitochondria ROS levels, preventing <z:chebi fb="0" ids="4056">cytochrome</z:chebi> C release to the cytoplasm and inhibiting caspase-3 activation </plain></SENT>
<SENT sid="8" pm="."><plain>Western blotting showed <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> activated the ROS-dependent nuclear factor-κB (NF-κB) signaling pathway, and <z:chebi fb="0" ids="28088">genistein</z:chebi> suppressed phosphorylation and activation of the NF-κB p65 subunit, as well as the phosphorylation and degradation of the inhibitor protein of κBα (IκBα) </plain></SENT>
<SENT sid="9" pm="."><plain>Our findings suggested that <z:chebi fb="0" ids="28088">genistein</z:chebi> has a neuroprotective effect in transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, which may involve regulation of mitochondria-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> pathways and suppression of ROS-induced NF-κB activation </plain></SENT>
</text></document>